IPIAD: an augmentation to standard treatment of PDAC using five repurposed drugs
“This paper presents the rationale for adding five already approved and marketed generic drugs from general medical practice to the current standard current first line chemotherapy for pancreatic ductal adenocarcinoma (PDAC).” Credit: 2024 Kast. “This paper presents the rationale for adding five already approved and marketed generic drugs from general medical practice to the […]
“This paper presents the rationale for adding five already approved and marketed generic drugs from general medical practice to the current standard current first line chemotherapy for pancreatic ductal adenocarcinoma (PDAC).”
Credit: 2024 Kast.
“This paper presents the rationale for adding five already approved and marketed generic drugs from general medical practice to the current standard current first line chemotherapy for pancreatic ductal adenocarcinoma (PDAC).”
BUFFALO, NY- February 9, 2024 – A new research perspective was published in Oncoscience (Volume 11) on February 7, 2024, entitled, “IPIAD- an augmentation regimen added to standard treatment of pancreatic ductal adenocarcinoma using already-marketed repurposed drugs irbesartan, pyrimethamine, itraconazole, azithromycin, and dapsone.”
In this new paper, researcher Richard E. Kast from IIAIGC Study Center presents the data and rationale for adding five generic non-oncology drugs from general medical practice to gemcitabine, nab-paclitaxel, a current standard cytotoxic chemotherapy of pancreatic ductal adenocarcinoma. The regimen, called IPIAD, uses an angiotensin receptor blocker (ARB) irbesartan indicated for treating hypertension, an old antimicrobial drug pyrimethamine indicated for treating toxoplasmosis or malaria, an old antifungal drug itraconazole, an old broad spectrum antibiotic azithromycin, and an old antibiotic dapsone.
“In reviewing selected growth driving systems active in pancreatic ductal adenocarcinoma then comparing these with detailed data on ancillary attributes of the IPIAD drugs, one can predict clinical benefit and slowing growth of pancreatic ductal adenocarcinoma by this augmentation regimen.”
Read the full paper: DOI: https://doi.org/10.18632/oncoscience.594
Correspondence to: Richard E. Kast
Email: richarderickast@gmail.com
Keywords: gemcitabine, multidrug, paclitaxel, pancreatic ductal adenocarcinoma, repurposed
About Oncoscience:
Oncoscience is a peer-reviewed, open-access, traditional journal covering the rapidly growing field of cancer research, especially emergent topics not currently covered by other journals. This journal has a special mission: Freeing oncology from publication cost. It is free for the readers and the authors.
To learn more about Oncoscience, visit Oncoscience.us and connect with us on social media:
- X, formerly known as Twitter
- YouTube
For media inquiries, please contact media@impactjournals.com.
Oncoscience Journal Office
6666 East Quaker Str., Suite 1D
Orchard Park, NY 14127
Phone: 1-800-922-0957, option 4
###
Journal
Oncoscience
DOI
10.18632/oncoscience.594
Method of Research
Commentary/editorial
Subject of Research
People
Article Title
IPIAD- an augmentation regimen added to standard treatment of pancreatic ductal adenocarcinoma using already-marketed repurposed drugs irbesartan, pyrimethamine, itraconazole, azithromycin, and dapsone
Article Publication Date
7-Feb-2024
What's Your Reaction?
